EUVIMEDEUVIMED entdecken
Open Access

Erythrocytosis in Gender-Affirming Care With Testosterone

Alana Tova Porat, Meghan Ellwood, Marisa Rodina, Shokoufeh Dianat

The Annals of Family Medicine · 2023-09 · 21 (5) · 403-407

DOI: 10.1370/afm.3018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Annals of Family Medicine, online erschienen am 25.09.2023. Verfasst von Alana Tova Porat und 3 weiteren Autor:innen. Beteiligte Einrichtung: Virginia Commonwealth University, Richmond, Virginia poratat@vcu.edu. Hauptthemen laut MEDLINE: Polycythemia, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 15-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Gender-affirming hormone therapy (GAHT) is safe overall, with few adverse effects. One potential effect from using testosterone for GAHT is an increase in hemoglobin and/or hematocrit, known as secondary erythrocytosis. Current guidelines recommend monitoring hemoglobin or hematocrit routinely in the first year, some as frequently as every 3 months, which can create barriers to care. Our study explored the incidence of erythrocytosis in the first 20 months of testosterone therapy among people receiving gender-affirming care. METHODS: This is a descriptive fixed cohort study of hematocrit and hemoglobin data from the charts of 282 people taking testosterone for GAHT. RESULTS: During the first 20 months of testosterone therapy, the cumulative incidence of hematocrit >50.4% was 12.6%, hematocrit >52% was 1.0%, and hematocrit >54% was 0.6%. All people were taking injectable testosterone cypionate, with a median dose of 100 mg weekly. CONCLUSION: Severe erythrocytosis (hematocrit >54%) is a rare outcome of gender-affirming testosterone therapy. Clinical recommendations should reconsider the need for routine frequent erythrocytosis screening within the first year of testosterone therapy for patients who prefer to minimize laboratory draws.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PolycythemiaDrug-Related Side Effects and Adverse ReactionsHumansCohort StudiesTestosteroneHemoglobins

Stichwörter der Autor:innen

erythrocytosisgender affirming caregender affirming hormone therapyguidelinetestosteronetransgender

Substanzen

TestosteroneHemoglobins

Autor:innen und Institutionen

  • Virginia Commonwealth University, Richmond, Virginia poratat@vcu.edu.
  • Virginia Commonwealth University, Richmond, Virginia.

Zitieren

APA

Porat, A. T., Ellwood, M., Rodina, M., & Dianat, S. (2023). Erythrocytosis in Gender-Affirming Care With Testosterone. The Annals of Family Medicine, 21(5), 403-407. https://doi.org/10.1370/afm.3018

Vancouver

Porat AT, Ellwood M, Rodina M, Dianat S. Erythrocytosis in Gender-Affirming Care With Testosterone. The Annals of Family Medicine. 2023;21(5):403-407. doi:10.1370/afm.3018

BibTeX
@article{Porat2023,
  author = {Porat, Alana Tova and Ellwood, Meghan and Rodina, Marisa and Dianat, Shokoufeh},
  title = {Erythrocytosis in Gender-Affirming Care With Testosterone},
  journal = {The Annals of Family Medicine},
  year = {2023},
  volume = {21},
  number = {5},
  pages = {403--407},
  doi = {10.1370/afm.3018}
}
Kostenlos starten →